PMID- 24168104
OWN - NLM
STAT- MEDLINE
DCOM- 20141124
LR  - 20181202
IS  - 1473-4877 (Electronic)
IS  - 0300-7995 (Linking)
VI  - 30
IP  - 3
DP  - 2014 Mar
TI  - Clinical management patterns and treatment outcomes in patients with non-small 
      cell lung cancer (NSCLC) across Europe: EPICLIN-Lung study.
PG  - 447-61
LID - 10.1185/03007995.2013.860372 [doi]
AB  - BACKGROUND: Throughout Europe, physicians face similar challenges in non-small 
      cell lung cancer (NSCLC) management, but comprehensive international information 
      on usual clinical practice is lacking so the burden of NSCLC is not fully 
      understood. METHODS: This multinational, multicentre, non-interventional study 
      (NCT00831909) was conducted in eight European countries. Patients with confirmed 
      NSCLC were consecutively enrolled from January to March 2009 and followed for 12 
      months or until death. Information was collected on patient and disease 
      characteristics, diagnosis and treatment patterns, and clinical outcomes. 
      Spontaneously reported adverse events (AEs) were also recorded. RESULTS: Data 
      were available for 3508 patients. Most patients (77.5%) were male, median (range) 
      age was 65.0 years (21.6-90.7), the majority of patients had a World Health 
      Organization performance status of </=1 (74.7%), and 10.8% were never smokers. The 
      most prevalent histologies were adenocarcinoma (43.8%) and squamous-cell 
      carcinoma (29.4%). Most patients presented with advanced disease (11.6% with 
      stage IIIA, 18.7% with stage IIIB, 48.6% with stage IV). In stage IV disease, 
      median progression-free survival and overall survival (months) by first-line 
      treatment cluster were platinum regimens: 6.5, 10.8; non-platinum regimens: 4.3, 
      8.5; regimens with bevacizumab 8.7, 12.9; investigational regimens: 5.6, 10.8; 
      best supportive care: 5.4, 6.6. The most frequently reported severe (Common 
      Terminology Criteria for Adverse Events v3.0>2) AEs were blood/bone marrow 
      (16.0%) and pulmonary/upper respiratory (7.8%). Key limitations of this study 
      related to its non-interventional nature and wide regional focus; for example, 
      achieving a representative sample of the overall NSCLC population, variation in 
      recruitment between countries, and data based on information from medical records 
      derived from routine visits. CONCLUSIONS: The Epidemiological Study to Describe 
      NSCLC Clinical Management Pattern in Europe-Lung (EPICLIN-Lung) study provides 
      new insights into the descriptive patterns and clinical management strategies for 
      NSCLC across Europe, and how they affect patient outcomes.
FAU - Carrato, A
AU  - Carrato A
AD  - Ramon y Cajal University Hospital , Madrid , Spain.
FAU - Vergnenegre, A
AU  - Vergnenegre A
FAU - Thomas, M
AU  - Thomas M
FAU - McBride, K
AU  - McBride K
FAU - Medina, J
AU  - Medina J
FAU - Cruciani, G
AU  - Cruciani G
LA  - eng
SI  - ClinicalTrials.gov/NCT00831909
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20131118
PL  - England
TA  - Curr Med Res Opin
JT  - Current medical research and opinion
JID - 0351014
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Carcinoma, Non-Small-Cell Lung/*therapy
MH  - Europe
MH  - Female
MH  - Humans
MH  - Lung Neoplasms/*therapy
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Young Adult
EDAT- 2013/10/31 06:00
MHDA- 2014/12/15 06:00
CRDT- 2013/10/31 06:00
PHST- 2013/10/31 06:00 [entrez]
PHST- 2013/10/31 06:00 [pubmed]
PHST- 2014/12/15 06:00 [medline]
AID - 10.1185/03007995.2013.860372 [doi]
PST - ppublish
SO  - Curr Med Res Opin. 2014 Mar;30(3):447-61. doi: 10.1185/03007995.2013.860372. Epub 
      2013 Nov 18.